Yves Jan Lambert Bodar

Yves Jan Lambert Bodar

Auto-generated profile, based on publicly available information

Yves Jan Lambert Bodar

Department of Urology, Amsterdam University Medical Centres (VU University), Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
BJB. H. E. Jansen
B. H. E. Jansen
YBY. J. L. Bodar
Y. J. L. Bodar
GZG. J. C. Zwezerijnen
G. J. C. Zwezerijnen
DMDennie Meijer
Dennie Meijer
JVJ. P. van der Voorn
J. P. van der Voorn
AVA. N. Vis
A. N. Vis
Purpose: The detection of lymph-node metastases (N1) with conventional imaging such as magnetic resonance imaging (MRI) and computed tomography (CT) is inadequate for primarily diagnosed prostate cancer (PCa). Prostate-specific membrane antigen (PSMA) PET/CT is successfully introduced for the staging of (biochemically) recurrent PCa. Besides the frequently used68gallium-labelled PSMA tracers,18fluorine-labelled PSMA tracers are available. This study examined the diagnostic accuracy of18F-DCFPyL (PSMA) PET/CT for lymph-node staging in primary PCa.Methods: This was a prospective, multicentre cohort study. Patients with primary PCa underwent18F-DCFPyL PET/CT prior to robot-assisted radical prostatectomy (RARP) with extended pelvic lymph-node dissection (ePLND). Patients were included between October 2017 and January 2020. A Memorial Sloan Kettering Cancer Centre (MSKCC) nomogram risk probability of ≥ 8% of lymph-node metastases was set to perform ePLND. All images were reviewed by two experienced nuclear physicians, and were compared with post-operative histopathologic results.Results: A total of 117 patients was analysed. Lymph-node metastases (N1) were histologically diagnosed in 17/117 patients (14.5%). The sensitivity, specificity, positive predictive value and negative predictive value for the18F-DCFPyL PET/CT detection of pelvic lymph-node metastases on a patient level were 41.2% (confidence interval (CI): 19.4–66.5%), 94.0% (CI 86.9–97.5%), 53.8% (CI 26.1–79.6%) and 90.4% (CI 82.6–95.0%), respectively.Conclusion: 18F-DCFPyL PET/CT showed a high specificity (94.4%), yet a limited sensitivity (41.2%) for the detection of pelvic lymph-node metastases in primary PCa. This implies that current PSMA PET/CT imaging cannot replace diagnostic ePLND. Further research is necessary to define the exact place of PSMA PET/CT imaging in the primary staging of PCa.

20 October 2020 in World Journal of Urology
Verified
Journal Article
Open access
PDF file
YBY. J. L. Bodar
Y. J. L. Bodar
BJB. H. E. Jansen
B. H. E. Jansen
JVJ. P. van der Voorn
J. P. van der Voorn
GZG. J. C. Zwezerijnen
G. J. C. Zwezerijnen
DMD. Meijer
D. Meijer
AVA. N. Vis
A. N. Vis
Purpose: In primary prostate cancer (PCa) patients, accurate staging and histologic grading are crucial to guide treatment decisions. 18F-DCFPyL (PSMA)-PET/CT has been successfully introduced for (re)staging PCa, showing high accuracy to localise PCa in lymph nodes and/or osseous structures. The diagnostic performance of 18F-DCFPyL-PET/CT in localizing primary PCa within the prostate gland was assessed, allowing for PSMA-guided targeted-prostate biopsy. Methods: Thirty patients with intermediate-/high-risk primary PCa were prospectively enrolled between May 2018 and May 2019 and underwent 18F-DCFPyL-PET/CT prior to robot-assisted radical prostatectomy (RARP). Two experienced and blinded nuclear medicine physicians assessed tumour localisation within the prostate gland on PET/CT, using a 12-segment mapping model of the prostate. The same model was used by a uro-pathologist for the RARP specimens. Based on PET/CT imaging, a potential biopsy recommendation was given per patient, based on the size and PET-intensity of the suspected PCa localisations. The biopsy recommendation was correlated to final histopathology in the RARP specimen. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for clinically significant PCa (csPCa, Gleason score ≥ 3 + 4 = 7) were assessed. Results: The segments recommended for potential targeted biopsy harboured csPCA in 28/30 patients (93%), and covered the highest Gleason score PCa segment in 26/30 patient (87%). Overall, 122 of 420 segments (29.0%) contained csPCa at final histopathological examination. Sensitivity, specificity, PPV and NPV for csPCa per segment using 18F-DCFPyL-PET/CT were 61.4%, 88.3%, 68.1% and 84.8%, respectively. Conclusions: When comparing the PCa-localisation on 18F-DCFPyL-PET/CT with the RARP specimens, an accurate per-patient detection (93%) and localisation of csPCa was found. Thus, 18F-DCFPyL-PET/CT potentially allows for accurate PSMA-targeted biopsy.

12 March 2022 in BJU International
Verified
Journal Article
Open access
YBYves J.L. Bodar
Yves J.L. Bodar
HVHans Veerman
Hans Veerman
DMDennie Meijer
Dennie Meijer
KBKatelijne de Bie
Katelijne de Bie
PLPim J. van Leeuwen
Pim J. van Leeuwen
AVAndré N. Vis
André N. Vis
Objectives: To investigate the association between intraprostatic, intratumoral maximum standardised uptake values (SUV max ) on prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer (PCa) prior to robot‐assisted radical prostatectomy (RARP) and pathology outcomes, including pathological International Society of Urological Pathology score (pISUP) and lymph node (LN) status (pN0/pN1). Patients and Methods: A bi‐centric, secondary analysis of two previous, prospective cohort studies was performed in 318 patients with biopsy confirmed PCa and who were scheduled for RARP. Before surgery, patients received a PSMA PET/CT with either 68 Ga‐PSMA‐11 (59% of the patients) or 18 F‐PSMA (DCFPyL; 41%) as radiotracer. PET/CT images were analysed both visually and semi‐quantitatively by measuring the SUV max of the most intense suspect lesion in the prostate. The association between the SUV max of the primary tumour and pre‐ and postoperative variables was analysed. Results: The SUV max was associated with clinical and biopsy preoperative variables, as well as with pISUP score and pathological tumour stage. Patients with a pISUP of ≤2 showed significantly lower SUV max compared to patients with a pISUP of >2 for both tracers (SUV max 18 F‐PSMA: median 5.1 vs 9.6, P = 0.002; SUV max 68 Ga‐PSMA‐11: 6.6 vs 8.6, P = 0.003). Moreover, patients with pN1 had significantly higher median SUV max than those with pN0/pNx for both tracers (SUV max 18 F‐PSMA: 7.9 vs 12.3, P = 0.04; SUV max 68 Ga‐PSMA‐11: 7.6 vs 12.0, P < 0.001). On multivariable logistic regression analysis, the intraprostatic SUV max was an independent predictor of pN1 for both 68 Ga‐PSMA‐11 (per doubling: odds ratio [OR] 1.96, 95% confidence interval [CI] 1.27–3.01)) and 18 F‐PSMA (per doubling: OR 1.79, 95% CI 1.06–3.03). Conclusion: Intraprostatic, intratumoral PSMA intensity on PET/CT, as semi‐quantitatively expressed by SUV max , may be a valuable innovative biomarker in patients with localised PCa, as it is highly associated with known conventional prognostic factors, such as pISUP and LN status.

2 November 2021 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
YBYves J. L. Bodar
Yves J. L. Bodar
BZBen G. J. C. Zwezerijnen
Ben G. J. C. Zwezerijnen
PVPatrick J. van der Voorn
Patrick J. van der Voorn
BJBernard H. E. Jansen
Bernard H. E. Jansen
RSRuth S. Smit
Ruth S. Smit
DODaniela E. Oprea-Lager
Daniela E. Oprea-Lager
Purpose: Multiparametric magnetic resonance imaging (mpMRI) is a well-established imaging method for localizing primary prostate cancer (PCa) and for guiding targeted prostate biopsies. [18F]DCFPyL positron emission tomography combined with MRI (PSMA-PET/MRI) might be of additional value to localize primary PCa. The aim of this study was to assess the diagnostic performance of [18F]DCFPyL-PET/MRI vs. mpMRI in tumour localization based on histopathology after robot-assisted radical-prostatectomy (RARP), also assessing biopsy advice for potential image-guided prostate biopsies. Methods: Thirty prospectively included patients with intermediate to high-risk PCa underwent [18F]DCFPyL-PET/MRI and mpMRI prior to RARP. Two nuclear medicine physicians and two radiologists assessed tumour localization on [18F]DCFPyL-PET/MRI and on mpMRI respectively, and gave a prostate biopsy advice (2 segments) using a 14-segment model of the prostate. The uro-pathologist evaluated the RARP specimen for clinically significant PCa (csPCa) using the same model. csPCa was defined as any PCa with Grade Group (GG) ≥ 2. The biopsy advice based on imaging was correlated with the final histology in the RARP specimen for a total-agreement analysis. An additional near-agreement correlation was performed to approximate clinical reality. Results: Overall, 142 of 420 (33.8%) segments contained csPCa after pathologic examination. The segments recommended for targeted biopsy contained the highest GG PCa segment in 27/30 patients (90.0%) both for [18F]DCFPyL-PET/MRI and mpMRI. Areas under the receiver operating characteristics curves (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for the total-agreement detection of csPCa per segment using [18F]DCFPyL-PET/MRI were 0.70, 50.0%, 89.9%, 71.7%, and 77.9%, respectively. These results were 0.75, 54.2%, 94.2%, 82.8%, and 80.1%, respectively, for mpMRI only. Conclusion: Both [18F]DCFPyL-PET/MRI and mpMRI were only partly able to detect csPCa on a per-segment basis. An accurate detection (90.0%) of the highest GG lesion at patient-level was observed when comparing both [18F]DCFPyL-PET/MRI and mpMRI biopsy advice with the histopathology in the RARP specimen. So, despite the finding that [18F]DCFPyL-PET/MRI adequately detects csPCa, it does not outperform mpMRI.

1 December 2021 in BJU International
Verified
Journal Article
Open access
PDF file
HVHans Veerman
Hans Veerman
MDMaarten Donswijk
Maarten Donswijk
EBElise Bekers
Elise Bekers
Judith Olde HeuvelJudith Olde Heuvel
Judith Olde Heuvel
YBYves J.L. Bodar
Yves J.L. Bodar
HPHenk G. van der Poel
Henk G. van der Poel
Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) is a modern imaging tool used in the diagnosis of prostate cancer (PCa). Approximately 10% of patients who underwent PSMA PET/CT have a biopsy-proven, primary PCa without PSMA expression on PET/CT (non-PSMAPET-expressing PCa), according to a recent systematic review[1]. However, the definition of non-PSMAPET-expression in these studies was poorly defined and no immunohistochemical studies for confirmation of PSMA protein expression were performed. The aim of this retrospective study was to report the prevalence, characteristics, and immunohistochemical assessment of non-PSMAPET-expressing hormone-sensitive PCa in a cohort of 362 patients who underwent PSMA PET/CT and robot-assisted radical prostatectomy (RARP).

13 September 2023 in BJU International
Verified
Journal Article
Open access
YBYves J.L. Bodar
Yves J.L. Bodar
LBLiselotte M.S. Boevé
Liselotte M.S. Boevé
PLPim J. van Leeuwen
Pim J. van Leeuwen
PBPhillippe C. Baars
Phillippe C. Baars
JNJakko A. Nieuwenhuijzen
Jakko A. Nieuwenhuijzen
AVAndré N. Vis
André N. Vis
Objective: To assess whether a diagnostic pathway in which prostate‐specific membrane antigen (PSMA) positron‐emission tomography (PET)/computed tomography (CT) is used as a single imaging modality is feasible to guide targeted biopsy and to detect clinically significant prostate cancer (csPCa) in biopsy‐naïve men at high‐risk of disease. Patients and Methods: A total of 60 men with a prostate‐specific antigen (PSA) level of 20–50 ng/mL underwent 18 F‐PSMA(DCFPyL)‐PET/CT prior to prostate biopsies in this prospective, non‐randomised cohort study. Magnetic resonance imaging (MRI) was not performed. Using a 12‐segment mapping model of the prostate, PSMA‐guided targeted biopsy was performed along with systematic biopsies. The detection rate of PCa and csPCa was assessed for combined systematic and targeted biopsy, and for targeted biopsy only. csPCa was defined as a prostate biopsy with an International Society of Uropathology (ISUP) Grade Group ≥2. Results: Lesions suspicious for PCa in the prostate gland were observed on all PSMA‐PET/CTs. A total of 27/60 men (45%) already had metastatic disease on staging 18 F‐PSMA(DCFPyL)‐PET/CT. Combined PSMA‐guided targeted and systematic biopsies detected PCa in 56/60 (93.3%) patients, with 52 of them (92.9%) having csPCa. PSMA‐guided targeted biopsy, if performed as a single biopsy modality, identified PCa in 52/60 men (86.7%) and in 27/27 men (100%) men with metastases. Conclusions: Using the PSMA‐driven single imaging modality pathway in biopsy‐naïve men at high‐risk of PCa, a substantial number of diagnostic MRI scans could be avoided while at the same time obtaining adequate targeting, staging, and detection of csPCa.